Fresenius Medical Care has launched the second tranche of its EUR 1 billion share buyback program, repurchasing approximately EUR 415 million of its own shares between January 12 and May 8, 2026. This accelerated timeline follows the completion of the first tranche ahead of schedule on December 29, 2025, and positions the company to finalize the entire program in under a year—significantly earlier than originally projected at its Capital Markets Day on June 17, 2025.

CEO Helen Giza highlighted that the rapid execution of the buyback is underpinned by strong cash-flow generation and sustained business momentum. CFO Martin Fischer echoed this, noting that the ‘‘FME Reignite’’ capital allocation framework has delivered consistent financial performance, enabling enhanced shareholder returns via accelerated share repurchases without compromising operating investments.

Fresenius Medical Care serves some 4.2 million dialysis patients globally through its network of 3,628 clinics and provides dialysis treatments for approximately 294,000 patients. The company will issue regular updates on buyback progress on its investor relations website, ensuring transparency for analysts and shareholders as the program advances toward completion.